Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Apr;63(4):503–507. doi: 10.1038/bjc.1991.120

Radioimmunotherapy of human hepatocellular carcinoma xenografts with 131I-labelled antiferritin antibody.

A F Saiful Alam 1
PMCID: PMC1972350  PMID: 2021533

Abstract

The effects of 131-labelled antiferritin polyclonal antibody for the treatment of established hepatocellular carcinoma (HC-04) in athymic nude mice were evaluated. 131I-labelled antiferritin antibody localised specifically to a subcutaneous tumour with a mean of 8.1% of the infused dose per gram of tumour at 24 h after infusion when the experiment was started 15 days after inoculation and with a mean of about 6.5% of the infused dose per gram of tumour when the experiment was started 30 days after tumour transplantation. The concentrations of 131I-antiferritin antibody in tumour delivered a mean of 1994 cGy to tumour following infusion of 500 microCi of radiolabelled antiferritin antibody in the early group and a mean of 1600 cGy in the late group. Treatment with 500 microCi led to regression of the tumour in 55% of animals in the early group and 44% in the late group. In contrast, unlabelled antiferritin and 131I-labelled IgG failed to exert any significant effect on tumour growth. The transplanted tumours in the early groups of animals had relatively higher concentration of ferritin than those in the late group. There was accelerated inhibition of tumour growth and prolonged survival in animals in the early group compared with those in the late group.

Full text

PDF
503

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Badger C. C., Krohn K. A., Peterson A. V., Shulman H., Bernstein I. D. Experimental radiotherapy of murine lymphoma with 131I-labeled anti-Thy 1.1 monoclonal antibody. Cancer Res. 1985 Apr;45(4):1536–1544. [PubMed] [Google Scholar]
  2. Baldwin R. W., Pimm M. V. Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targeting. Cancer Metastasis Rev. 1983;2(1):89–106. doi: 10.1007/BF00046907. [DOI] [PubMed] [Google Scholar]
  3. Cohen C., Berson S. D., Shulman G., Budgeon L. R. Immunohistochemical ferritin in hepatocellular carcinoma. Cancer. 1984 May 1;53(9):1931–1935. doi: 10.1002/1097-0142(19840501)53:9<1931::aid-cncr2820530921>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  4. Cohen C., Berson S. D., Shulman G., Budgeon L. R. Liver iron stores and hepatitis B antigen status. Cancer. 1985 Nov 1;56(9):2201–2204. doi: 10.1002/1097-0142(19851101)56:9<2201::aid-cncr2820560911>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  5. Epenetos A. A., Nimmon C. C., Arklie J., Elliott A. T., Hawkins L. A., Knowles R. W., Britton K. E., Bodmer W. F. Detection of human cancer in an animal model using radio-labelled tumour-associated monoclonal antibodies. Br J Cancer. 1982 Jul;46(1):1–8. doi: 10.1038/bjc.1982.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kew M. C., Torrance J. D., Derman D., Simon M., Macnab G. M., Charlton R. W., Bothwell T. H. Serum and tumour ferritins in primary liver cancer. Gut. 1978 Apr;19(4):294–299. doi: 10.1136/gut.19.4.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Klein J. L., Nguyen T. H., Laroque P., Kopher K. A., Williams J. R., Wessels B. W., Dillehay L. E., Frincke J., Order S. E., Leichner P. K. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma. Cancer Res. 1989 Nov 15;49(22):6383–6389. [PubMed] [Google Scholar]
  8. Larson S. M., Carrasquillo J. A., Krohn K. A., Brown J. P., McGuffin R. W., Ferens J. M., Graham M. M., Hill L. D., Beaumier P. L., Hellström K. E. Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest. 1983 Dec;72(6):2101–2114. doi: 10.1172/JCI111175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Leichner P. K., Klein J. L., Siegelman S. S., Ettinger D. S., Order S. E. Dosimetry of 131I-labeled antiferritin in hepatoma: specific activities in the tumor and liver. Cancer Treat Rep. 1983 Jul-Aug;67(7-8):647–658. [PubMed] [Google Scholar]
  10. Liu K. D., Tang Z. Y., Bao Y. M., Lu J. Z., Qian F., Yuan A. N., Zhao H. Y. Radioimmunotherapy for hepatocellular carcinoma (HCC) using 131I-anti HCC isoferritin IgG: preliminary results of experimental and clinical studies. Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):319–323. [PubMed] [Google Scholar]
  11. Lundstedt C., Ekberg H., Halldorsdottir A., Tranberg K. G., Stigsson L. Angiography as diagnostic, prognostic and therapeutic tool in liver metastases from a colo-rectal primary tumor. Acta Radiol Diagn (Stockh) 1985 Jul-Aug;26(4):373–380. doi: 10.1177/028418518502600403. [DOI] [PubMed] [Google Scholar]
  12. Moshakis V., McIlhinney R. A., Raghavan D., Neville A. M. Localization of human tumour xenografts after i.v. administration of radiolabeled monoclonal antibodies. Br J Cancer. 1981 Jul;44(1):91–99. doi: 10.1038/bjc.1981.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mènard S., Miotti S., Tagliabue E., Parmi L., Buraggi G. L., Colnaghi M. I. Tumor radioimmunolocalization in a murine system using monoclonal antibodies. Tumori. 1983 Jun 30;69(3):185–190. doi: 10.1177/030089168306900302. [DOI] [PubMed] [Google Scholar]
  14. Order S. E., Klein J. L., Leichner P. K., Ettinger D. S., Kopher K., Finney K., Surdyke M., Leibel S. A. Radiolabeled antibody in the treatment of primary and metastatic liver malignancies. Recent Results Cancer Res. 1986;100:307–314. doi: 10.1007/978-3-642-82635-1_38. [DOI] [PubMed] [Google Scholar]
  15. Oren J. W., Folse R., Kraudel K. L., Lewis D. B. The preoperative liver scan and surgical decision-making in patients with colorectal cancer. Am J Surg. 1986 Apr;151(4):452–456. doi: 10.1016/0002-9610(86)90101-7. [DOI] [PubMed] [Google Scholar]
  16. PRESSMAN D. Radiolabeled antibodies. Ann N Y Acad Sci. 1957 Dec 16;69(4):644–650. doi: 10.1111/j.1749-6632.1957.tb49702.x. [DOI] [PubMed] [Google Scholar]
  17. Rostock R. A., Klein J. L., Leichner P., Kopher K. A., Order S. E. Selective tumor localization in experimental hepatoma by radiolabeled antiferritin antibody. Int J Radiat Oncol Biol Phys. 1983 Sep;9(9):1345–1350. doi: 10.1016/0360-3016(83)90266-3. [DOI] [PubMed] [Google Scholar]
  18. Rostock R. A., Kopher K. A., Bauer T. W., Klein J. L. Factors that affect antiferritin localization in four rat hepatoma models. Cancer Drug Deliv. 1985 Spring;2(2):139–145. doi: 10.1089/cdd.1985.2.139. [DOI] [PubMed] [Google Scholar]
  19. Tang Z. Y., Liu K. D., Bao Y. M., Lu J. Z., Yu Y. Q., Ma Z. C., Zhou X. D., Yang R., Gan Y. H., Lin Z. Y. Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second-look resection. Cancer. 1990 Jan 15;65(2):211–215. doi: 10.1002/1097-0142(19900115)65:2<211::aid-cncr2820650205>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  20. Tang Z. Y., Lui K. D., Guo Y. D., Ma Z. C., Yu D., Yu Z. Y., Boa Y. M., Lu J. Z., Lin Z. Y., Yu Y. Q. Tumor imaging and targeting therapy for hepatocellular carcinoma. Preliminary results of experimental and clinical studies. Chin Med J (Engl) 1986 Nov;99(11):855–860. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES